Therapeutic Implications and Mechanisms of Cyclin E - Khandan Keyomarsi

Abstract

Funding Agency

Agency: National Institute of Health (NIH)
Institute: National Cancer Institute (NCI)
Type: First Independent Research Support & Transition (FIRST) Awards (R29)
Project #: 1R29CA066062-01A1
Application #: 2109297
Study Section: Experimental Therapeutics Subcommittee 1 (ET)

Project Start: 1996-08-01
Project End: 2001-07-31
Budget Start: 1996-08-01
Budget End: 1997-07-31
Support Year: 1
Fiscal Year: 1996
Total Cost
Indirect Cost

Institution

Name: Wadsworth Center
Department
Type
DUNS #: 110521739

City: Menands
State: NY
Country: United States
Zip Code: 12204

Related projects


NIH 2000 R29 CA	Therapeutic Implications and Mechanisms of Cyclin E Keyomarsi, Khandan / University of Texas MD Anderson Cancer Center	$115,098
NIH 1999 R29 CA	Therapeutic Implications and Mechanisms of Cyclin E Keyomarsi, Khandan / Wadsworth Center
NIH 1998 R29 CA	Therapeutic Implications and Mechanisms of Cyclin E Keyomarsi, Khandan / Wadsworth Center
NIH 1997 R29 CA	Therapeutic Implications and Mechanisms of Cyclin E Keyomarsi, Khandan / Wadsworth Center
NIH 1996 R29 CA	Therapeutic Implications and Mechanisms of Cyclin E Keyomarsi, Khandan / Wadsworth Center

Publications

Chen, X; Lowe, M; Herliczek, T et al. (2000) Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest. J Natl Cancer Inst 92:1999-2008

Rao, S; Gray-Bablin, J; Herliczek, T W et al. (1999) The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is posttranscriptionally regulated and independent of the PKA pathway. Exp Cell Res 252:211-23

Gray-Bablin, J; Rao, S; Keyomarsi, K (1997) Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res 57:604-9

Comments

Be the first to comment on Khandan Keyomarsi's grant